CMS expands Medicare Advantage RADV audits to all eligible plans

Aug. 2025What's New

On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.

Beginning in June 2025, CMS will audit all eligible Medicare Advantage contracts for payment years 2019 through 2023, a significant increase from the previous scope of approximately 60 plans annually. This expansion includes UPMC Health Plan.

 As part of this initiative, CMS will also increase the number of medical records reviewed per plan—from a standard 35 records annually to 35 to 200 records per plan per year, depending on the plan’s size. This enhanced sampling methodology is designed to improve the statistical validity of audit findings and support extrapolation in accordance with the RADV Final Rule.

 UPMC Health Plan began requesting medical records for this expanded CMS audit starting in June 2025. Record requests will cover dates of service from 2018 through 2023. Affected providers will be contacted directly with detailed instructions, including member information, relevant dates of service, and documentation requirements.

Thank you in advance for your prompt attention to such requests.


Recent Announcements

Clinical workflow changes through Epic®

Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.
Sep. 2026Important Notices

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Sep. 2026Education/Webinars

Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)

Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).
Sep. 2026Pharmacy Updates